HYDERGINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYDERGINE (HYDERGINE).
Ergoloid mesylates (Hydergine) are a mixture of dihydrogenated ergot alkaloids that act as non-selective dopamine D1 and D2 receptor agonists and serotonin receptor antagonists. They enhance cerebral blood flow and neuronal metabolism, and modulate neurotransmitter activity.
| Metabolism | Hepatic via cytochrome P450 enzymes (CYP3A4 primarily). |
| Excretion | Primarily fecal (80%) via biliary excretion; renal excretion accounts for <10% of unchanged drug. |
| Half-life | Terminal elimination half-life is 12-15 hours; clinically, steady-state is achieved within 3-5 days. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 1.5-2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Sublingual: ~25-50% due to first-pass metabolism; oral: <25% due to extensive hepatic first-pass effect. |
| Onset of Action | Sublingual: 15-30 minutes; oral: 30-60 minutes. |
| Duration of Action | Sublingual: 4-6 hours; oral: 4-6 hours; effect may persist longer due to active metabolites. |
| Action Class | Nootropic agent |
1-2 mg orally three times daily.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment; use caution in severe impairment. |
| Liver impairment | Contraindicated in Child-Pugh class B and C. |
| Pediatric use | Not recommended; safety and efficacy in pediatric patients have not been established. |
| Geriatric use | Dose reduction may be necessary due to increased sensitivity; start at lower end of dosing range. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HYDERGINE (HYDERGINE).
| Breastfeeding | Hydergine is contraindicated in breastfeeding due to potential for ergotism in infants (vomiting, diarrhea, convulsions). Ergoloid mesylates may suppress lactation via dopaminergic activity. M/P ratio unknown; avoid use. |
| Teratogenic Risk | Ergoloid mesylates (Hydergine) are ergot derivatives with potential uterotonic and vasoconstrictive effects. First trimester: Limited human data; animal studies suggest increased risk of skeletal and visceral malformations at high doses. Avoid use. Second trimester: Potential for reduced uterine blood flow leading to fetal hypoxia and growth restriction. Contraindicated. Third trimester: Risk of premature labor, fetal distress, and placental insufficiency due to ergot-induced vasospasm. Contraindicated. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to ergot alkaloids","Acute psychosis","Severe hypotension","Concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals, protease inhibitors) due to risk of ergotism"]
| Precautions | ["May cause hypotension, especially orthostatic","Use with caution in patients with bradycardia or severe cardiac disease","May cause gastrointestinal disturbances","Not effective for acute or rapidly progressive dementia"] |
| Food/Dietary | No specific food interactions reported. Avoid excessive caffeine or nicotine as they may counteract effects. Limit alcohol. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, uterine activity, and fetal heart rate if inadvertent exposure occurs. Assess for signs of ergotism (numbness, tingling, muscle cramps). If chronic exposure, fetal growth ultrasound recommended. |
| Fertility Effects | Ergoloid mesylates may increase serum prolactin levels (though typical ergots are prolactin-lowering; Hydergine has mixed dopaminergic/antidopaminergic effects). Potential reversible menstrual irregularities and anovulation. Effects on spermatogenesis unknown. |
| Clinical Pearls |
| HYDERGINE is a combination of ergoloid mesylates previously used for age-related cognitive decline. Efficacy is controversial; most guidelines do not recommend its use. Can cause bradycardia, orthostatic hypotension, and gastrointestinal disturbances. Avoid in patients with psychosis, severe bradycardia, or history of ergot alkaloid hypersensitivity. Not FDA-approved for dementia. |
| Patient Advice | Take exactly as prescribed; do not change dose without consulting your doctor. · May cause dizziness or lightheadedness upon standing; rise slowly from sitting or lying positions. · Avoid alcohol as it may increase side effects like dizziness or drowsiness. · Report any slow heart rate, fainting, or severe nausea/vomiting to your healthcare provider. · This medication is not a cure for dementia and has limited evidence of benefit. |